HPV9 vaccine to be added to national immunisation schedules from January 2027

HPV9 will replace HPV2 for female students who have yet to start or complete their vaccination series under the Health Promotion Board's school-based programme.

A box of Gardasil 9 human papillomavirus virus (HPV) vaccine. (File photo: AFP/Patrick T Fallon)

This audio is generated by an AI tool.

SINGAPORE: The human papillomavirus 9-valent (HPV9) vaccine will be added to national immunisation schedules next year, health authorities said on Friday (Oct 2), giving eligible female Singaporeans and permanent residents broader protection against cervical cancer.

From Jan 1, 2027, the HPV9 vaccine will be added to the National Childhood Immunisation Schedule (NCIS), National Adult Immunisation Schedule (NAIS) and Subsidised Vaccine List (SVL), said the Ministry of Health (MOH), Health Promotion Board (HPB) and Communicable Diseases Agency (CDA) in a joint release.

“The HPV9 vaccine, also known as Gardasil 9, will be included in the NCIS and NAIS for females aged 9 to 26,” said the authorities. “The HPV2 vaccine, also known as Cervarix, will remain on both schedules as an alternative option.”

Human papillomavirus, or HPV, is the most common sexually transmitted infection worldwide, with nearly 80 per cent of men and women infected at some point in their lives. It can cause cervical cancer, as well as cancers of the anus, throat, vulva, vagina and penis.

CNA Games Guess Word Crack the word, one row at a time Buzzword Create words using the given letters Mini Sudoku Tiny puzzle, mighty brain teaser Mini Crossword Small grid, big challenge Word Search Spot as many words as you can Show More Show Less In Singapore, HPV vaccination is recommended for females aged 9 to 26 for the prevention of cervical cancer. “Both the HPV2 and HPV9 vaccines protect against HPV types 16 and 18, which cause 70 per cent of all cervical cancers,” said MOH, HPB and CDA on Friday. “The HPV9 vaccine provides broader protection by also covering additional HPV types that account for a further 20 per cent of cervical cancers, bringing its total coverage to approximately 90 per cent.” Under the updated recommendations, unvaccinated females may start their vaccination series with either HPV2 or HPV9. Two doses are recommended for those receiving their first dose from age 9 to 14, while three doses are recommended for those receiving their first dose from age 15 to 26. If HPV vaccination is started but not completed by age 26, the remaining doses may be taken after age 26, as soon as possible and up to age 45, said the authorities. Females who started their vaccination series with HPV2 or HPV4 and have remaining doses may complete the series with HPV9. HPV4, previously known as Gardasil, is no longer available in Singapore and has been removed from the NCIS and NAIS. “Studies have shown that such mixed HPV vaccination schedules are safe and provide protection against the HPV strains covered by both vaccines,” said MOH, HPB and CDA. Those who have completed their recommended HPV vaccination schedules are not recommended to receive additional HPV9 doses.

In Singapore, HPV vaccination is recommended for females aged 9 to 26 for the prevention of cervical cancer.

“Both the HPV2 and HPV9 vaccines protect against HPV types 16 and 18, which cause 70 per cent of all cervical cancers,” said MOH, HPB and CDA on Friday.

“The HPV9 vaccine provides broader protection by also covering additional HPV types that account for a further 20 per cent of cervical cancers, bringing its total coverage to approximately 90 per cent.”

Under the updated recommendations, unvaccinated females may start their vaccination series with either HPV2 or HPV9.

Two doses are recommended for those receiving their first dose from age 9 to 14, while three doses are recommended for those receiving their first dose from age 15 to 26.

If HPV vaccination is started but not completed by age 26, the remaining doses may be taken after age 26, as soon as possible and up to age 45, said the authorities.

Females who started their vaccination series with HPV2 or HPV4 and have remaining doses may complete the series with HPV9. HPV4, previously known as Gardasil, is no longer available in Singapore and has been removed from the NCIS and NAIS.

“Studies have shown that such mixed HPV vaccination schedules are safe and provide protection against the HPV strains covered by both vaccines,” said MOH, HPB and CDA.

Those who have completed their recommended HPV vaccination schedules are not recommended to receive additional HPV9 doses.

HPV9 REPLACES HPV2 IN SCHOOLS

Under HPB’s school-based HPV vaccination programme, Secondary 1 and 2 female students are offered HPV vaccination at no charge.

From Jan 1, 2027, HPV9 will replace HPV2 for female students who have yet to start or complete their vaccination series under the programme. Female students in the 2026 Secondary 1 cohort who received HPV2 as their first dose will receive HPV9 as their second dose in 2027.

According to MOH's vaccination website, HPV2 is registered for use in females, while HPV9 is registered for both females and males. Government subsidies and MediSave are currently not available for HPV9 vaccination.

At Singapore Women's Clinic, for example, HPV9 currently costs more than twice as much as HPV2, at S$250 (US$195) per dose compared with S$96 per dose, according to its website.

From Jan 1, 2027, eligible Singaporean children will receive full subsidies for HPV9 vaccination at CHAS GP clinics and polyclinics, while eligible Singaporean adults can receive means-tested subsidies of up to 75 per cent at these settings.

Eligible permanent residents can receive subsidies at polyclinics.

MediSave use will also be extended to HPV9 vaccination for people in the recommended groups from Jan 1, subject to the prevailing MediSave Chronic and Preventive Care withdrawal limits.

Vaccination subsidies and MediSave use will not be applicable to additional doses of the HPV9 vaccine for those who have already completed the recommended doses.

Eligible individuals can book HPV vaccination appointments at participating CHAS GP clinics through vaccine.gov.sg or make an appointment at polyclinics. HPV9 vaccination under the updated schedules will be available from Jan 1.

Get our pick of top stories and thought-provoking articles in your inbox

Stay updated with notifications for breaking news and our best stories

Join our channel for the top reads for the day on your preferred chat app

在新加坡健康促进局的校内疫苗接种计划下，HPV9 将取代 HPV2，为尚未开始或完成疫苗接种的女学生提供疫苗接种。

一盒加卫苗9价人乳头瘤病毒（HPV）疫苗。（资料照片：法新社/帕特里克·T·法伦）

这段音频由人工智能工具生成。

新加坡：卫生部门周五（10月2日）表示，9价人乳头瘤病毒（HPV9）疫苗将于明年纳入国家免疫计划，为符合条件的新加坡女性公民和永久居民提供更广泛的宫颈癌防护。

卫生部、健康促进局和传染病机构在一份联合声明中表示，从 2027 年 1 月 1 日起，HPV9 疫苗将被纳入国家儿童免疫计划 (NCIS)、国家成人免疫计划 (NAIS) 和补贴疫苗清单 (SVL)。

当局表示：“HPV9疫苗（也称加卫苗9）将纳入9至26岁女性的全国免疫接种计划（NCIS）和全国免疫接种计划（NAIS）。HPV2疫苗（也称Cervarix）将继续保留在两个计划中，作为备选方案。”

人乳头瘤病毒（HPV）是全球最常见的性传播感染，近80%的男性和女性在其一生中的某个阶段都会感染。它可导致宫颈癌，以及肛门癌、咽喉癌、外阴癌、阴道癌和阴茎癌。

CNA游戏 猜词游戏 逐行破解单词 流行词游戏 用给定的字母组成单词 迷你数独 小谜题，脑力挑战 迷你填字游戏 小方格，大挑战 单词搜索 尽可能多地找出单词 显示更多 显示更少 在新加坡，建议9至26岁的女性接种HPV疫苗，以预防宫颈癌。卫生部、保健促进局和社区发展局周五表示：“HPV2和HPV9疫苗均可预防HPV 16型和18型病毒感染，这两种病毒导致70%的宫颈癌病例。HPV9疫苗的保护范围更广，还能覆盖其他导致宫颈癌的HPV类型（约占20%），使其总覆盖率达到约90%。” 根据更新后的建议，未接种疫苗的女性可以选择接种HPV2或HPV9疫苗开始接种程序。建议9至14岁首次接种HPV疫苗者接种两剂，15至26岁首次接种者接种三剂。卫生部表示，如果26岁开始接种HPV疫苗但未完成，剩余剂次可在26岁后尽快接种，最晚可至45岁。已接种HPV2或HPV4疫苗且仍有剩余剂次的女性，可接种HPV9疫苗完成接种。HPV4疫苗（原名加卫苗）已在新加坡停用，并已从国家免疫计划（NCIS）和国家免疫计划（NAIS）中移除。卫生部、健康促进局和儿童发展署表示：“研究表明，这种混合HPV疫苗接种方案是安全的，能够有效预防两种疫苗所涵盖的HPV病毒株。” 已完成推荐HPV疫苗接种方案者，不建议接种额外的HPV9疫苗。

在新加坡，建议 9 至 26 岁的女性接种 HPV 疫苗，以预防宫颈癌。

卫生部、保健促进局和社区发展局周五表示：“HPV2 和 HPV9 疫苗均可预防 HPV 16 型和 18 型病毒感染，这两种病毒导致 70% 的宫颈癌。”

“HPV9疫苗通过覆盖其他HPV类型（这些类型占宫颈癌病例的20%）提供更广泛的保护，使其总覆盖率达到约90%。”

根据更新后的建议，未接种疫苗的女性可以从 HPV2 或 HPV9 开始接种疫苗。

对于 9 至 14 岁首次接种疫苗的人，建议接种两剂；对于 15 至 26 岁首次接种疫苗的人，建议接种三剂。

当局表示，如果26岁开始接种HPV疫苗但未完成，剩余的剂量可以在26岁以后尽快接种，最晚可至45岁。

已接种HPV2或HPV4疫苗且仍有剩余剂次的女性，可接种HPV9完成整个疫苗接种程序。HPV4疫苗（以前称为加卫苗）已在新加坡停用，并已从国家免疫计划（NCIS）和国家免疫计划（NAIS）中移除。

卫生部、HPB 和 CDA 表示：“研究表明，这种混合 HPV 疫苗接种方案是安全的，并且可以预防两种疫苗所涵盖的 HPV 毒株。”

已完成推荐HPV疫苗接种计划的人不建议再接种HPV9疫苗。

HPV9 取代 HPV2 在学校进行疫苗接种

根据新加坡卫生促进局的学校HPV疫苗接种计划，中学一年级和二年级的女生可免费接种HPV疫苗。

自2027年1月1日起，HPV9将取代HPV2，用于尚未开始或完成疫苗接种计划的女学生。2026届中一女生若第一剂接种的是HPV2，则将于2027年接种第二剂HPV9。

根据卫生部疫苗接种网站的信息，HPV2疫苗已注册用于女性，而HPV9疫苗则男女均可接种。目前，HPV9疫苗接种不享受政府补贴和保健储蓄计划（MediSave）的优惠。

例如，据新加坡妇女诊所网站显示，HPV9 目前的价格是 HPV2 的两倍多，每剂 250 新元（195 美元），而 HPV2 每剂 96 新元。

从 2027 年 1 月 1 日起，符合条件的新加坡儿童将在 CHAS 全科医生诊所和综合诊所获得 HPV9 疫苗的全额补贴，而符合条件的新加坡成年人可以在这些场所获得高达 75% 的经济状况调查补贴。

符合条件的永久居民可在综合诊所领取补贴。

从 1 月 1 日起，保健储蓄账户的使用范围也将扩大到为推荐人群接种 HPV9 疫苗，但须遵守现行的保健储蓄慢性病和预防保健提取限额。

对于已经完成推荐剂次HPV9疫苗接种的人，疫苗补贴和保健储蓄金将不适用于额外剂次的HPV9疫苗接种。

符合资格的人士可通过 vaccine.gov.sg 网站预约在参与活动的 CHAS 全科诊所接种 HPV 疫苗，或前往综合诊疗所预约。根据更新后的接种时间表，HPV9 疫苗将于 1 月 1 日起开始接种。

订阅我们的邮件，即可获取精选热点新闻和引人深思的文章。

订阅通知，第一时间获取突发新闻和精彩报道。

加入我们的频道，即可在您常用的聊天应用上获取当日热门文章。